HighTower Advisors
INDV icon

HighTower Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

HighTower Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41M Buy
83,088
+72,870
+713% +$2.64M ﹤0.01% 1453
2026
Q1 		$311K Buy
+10,218
New +$337K ﹤0.01% 3146

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's INDV Position: Q2 2026 in Review

HighTower Advisors increased its Indivior Pharmaceuticals (INDV) stake by 713% in Q2 2026, buying an estimated $2.64M and bringing the position to 83,088 shares worth $3.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1453.

HighTower Advisors first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • HighTower Advisors held 83,088 shares of Indivior Pharmaceuticals worth $3.41M as of Q2 2026.
  • HighTower Advisors bought 72,870 Indivior Pharmaceuticals shares in Q2 2026, an estimated $2.64M.
  • Indivior Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #1453 holding.
  • HighTower Advisors first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.